Morning Movers 06/04: (CBLI) (MTOX) (CRED) Higher; (BONT) (CYTR) Lower

June 4, 2012 10:35 AM EDT Send to a Friend
Get Alerts CBLI Hot Sheet
Trade CBLI Now!
Cleveland Biolabs (Nasdaq: CBLI) 63.8% HIGHER; reported strong survival results for its randomized, blinded, placebo-controlled efficacy study of CBLB502 in 179 non-human primates (NHPs) conducted under Good Laboratory Practice (GLP) with elements of Good Clinical Practice (GCP), as required by the U.S. FDA Animal Rule. The study demonstrated with a high degree of statistical significance the dose-response relationship between the administration of CBLB502 and the survival of lethally irradiated animals, the study's primary endpoint. Click here to see the full report.

MEDTOX Scientific, Inc. (Nasdaq: MTOX) 35.6% HIGHER; Laboratory Corporation of America Holdings (NYSE: LH) and MEDTOX today announced that they had entered into a definitive merger agreement under which LabCorp would acquire MEDTOX for a purchase price of $27.00 per share in cash

Credo Petroleum (Nasdaq: CRED) 31.9% HIGHER; Forestar (NYSE: FOR) will acquire the company for $14.50/share, or approximately $146 million in the aggregate. The transaction has also been approved by the board of directors of Forestar.

Inphi Corp. (NYSE: IPHI) 14.6% HIGHER; Piper Jaffray upgraded Inphi from Neutral to Overweight with a price target of $12.00.

Galena Biopharma (Nasdaq: GALE) 14% HIGHER; The Phase 1/2 clinical trials evaluated the NeuVax (E75) vaccine, an HLA A2/A3 restricted HER2/neu (HER2) peptide, mixed with GM-CSF. The trials (SN-33 (Node Positive) and SN-34 (Node Negative)) evaluated a combined 187 patients and have completed a median 60-months of follow-up, with the final patients expected to complete their booster treatments and final follow-up visits by September 2012. The final data analysis is expected to be reported in the fourth quarter of this year. Click here to see the full report.

Bon-Ton Stores (Nasdaq: BONT) 13.4% LOWER; traders are continuing to take profits following a recent run up. The stock fell nearly 8 percent on Friday, pushing below a technical level at $5.

CytRx (Nasdaq: CYTR) 10.6% LOWER; investors taking profits following a 30 percent rise over the last few weeks.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Special Reports

Related Entities

Piper Jaffray, Morning Movers

Add Your Comment